<?xml version='1.0' encoding='utf-8'?>
<document id="26894507"><sentence text="Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors."><entity charOffset="209-217" id="DDI-PubMed.26894507.s1.e0" text="Tyrosine" /></sentence><sentence text="Antacid treatments decrease the serum concentrations of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), although it is unknown whether antacids affect clinical outcomes" /><sentence text=" As cerebrospinal fluid concentrations of TKIs are much lower than serum concentrations, we hypothesized that this drug-drug interaction might affect the prognosis of patients with de novo brain metastases" /><sentence text="" /><sentence text="This retrospective study evaluated 269 patients with EGFR-mutant non-small cell lung cancer (NSCLC) who had been diagnosed between December 2010 and December 2013, and had been treated using first-line first-generation EGFR-TKIs" /><sentence text=" Among these patients, we identified patients who concurrently used H2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) as antacids" /><sentence text=" Patients who exhibited &gt;30% overlap between the use of TKIs and antacids were considered antacid users" /><sentence text="" /><sentence text="Fifty-seven patients (57/269, 21" /><sentence text="2%) were antacid users, and antacid use did not significantly affect progression-free survival (PFS; no antacids: 11" /><sentence text="2 months, H2RAs: 9" /><sentence text="4 months, PPIs: 6" /><sentence text="7 months; p = 0" /><sentence text="234)" /><sentence text=" However, antacid use significantly reduced overall survival (OS; no antacids: 25" /><sentence text="0 months, H2RAs: 15" /><sentence text="5 months, PPIs: 11" /><sentence text="3 months; p = 0" /><sentence text="002)" /><sentence text=" Antacid use did not affect PFS for various metastasis sites, although antacid users with de novo brain metastases exhibited significantly shorter OS, compared to non-users (11" /><sentence text="8 vs" /><sentence text=" 16" /><sentence text="3 months, respectively; p = 0" /><sentence text="041)" /><sentence text=" Antacid use did not significantly affect OS in patients with bone, liver, or pleural metastases" /><sentence text="" /><sentence text="Antacid use reduced OS among patients with EGFR-mutant NSCLC who were treated using first-line first-generation EGFR-TKIs, and especially among patients with de novo brain metastases" /><sentence text="" /></document>